Information Provided By:
Fly News Breaks for August 8, 2019
Aug 8, 2019 | 07:24 EDT
Canaccord analyst Arlinda Lee raised her price target on Xencor to $52 from $45 citing its commercial product Xtend which is already generating sales, multiple partnered programs, and wholly owned programs progressing through the clinic. Lee reiterated her Buy rating on Xencor shares.